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New publishers for British Journal of Cancer
On behalf of fellow Editors, members of the Editorial Board and
the staffofBritish JournalofCancer, I welcome ourreaders to this
first issue of the journal under our new publishers. After many
years of working closely and productively with the previous
publishers, Stockton Press, the owners of the journal, the Cancer
Research Campaign, decided to contract future publication of
the journal to Churchill Livingstone as from January 1997. In
looking forward to our future collaboration, I would first wish to
acknowledge the successful collaboration with Stockton Press that
I enjoyed at all levels since my appointment as Editor in 1994.
I am confident that the new association between the Cancer
Research Campaign and Churchill Livingstone will continue to
foster the development ofBritish Journal ofCancer as one of the
world's leading journals reporting research across the entire field
ofcancer research.
The contents of thejournal include primary reports of research
in cellular and molecular biology, pathology, experimental thera-
peutics, epidemiology and diverse clinical studies. From time to
time, the journal publishes timely state-of-the-art reviews, edito-
rials on 'hot' issues, research correspondence, book reviews, a
calendar of scientific meetings and conferences and occasionally
conference supplements. The policy will not change and I urge
our readers worldwide to continue to consider British Journal of
Cancer as the medium ofpublication for their research.
British Journal ofCancer is truly an international journal. Over
70% of our published papers originate from outside the United
Kingdom and include manuscripts submitted from centres in
Europe, the Americas and the countries ofAsia and Australasia.
The journal continues to grow both in content and stature. At
present we receive manuscripts at the rate of about 1200 per year.
This figure has been growing steadily for several years and is
reflected in the decision to publish the journal biweekly as from
January 1996. This increase has occurred in all subject areas, but
particularly epidemiology, where the submission rate has increased
from 70 in 1993/94 to 125 in 1995/96.
The increased stature of the journal is reflected by the upward
trend in the journal's impact factor computed by the Institute for
Scientific Information (ISI). The figures forrecent years are: 1992 -
2.798; 1993 - 2.893; 1994 - 3.188; 1995 - 3.499. We expect this
figure to increase further, particularly in view ofthe change in 1996
from 12 to 24 issues per year.
We seek to increase further the subscription circulation of the
journal. Special discount rates can be negotiated for appropriate
societies that might wish to make the journal more widely avail-
able to their membership. I urge society members, and other inter-
ested researchers, to consider taking out a personal subscription to
British Journal of Cancer. The increased number of issues per
year, coupled with increasing circulation, will ultimately resultin a
better deal for all readers.
It is with much regret that we learned earlier in the year that our
Clinical Editor, Stan Kaye, who has served thejournal so well over
several years, has decided to stand down at the end of 1996. We
wish him well and thankhim forhis sterling efforts. In his place we
offer a warm welcome to Bob Hawkins as the new Clinical Editor.
Like our other Editors, he will have a busy time! In 1995/96, over
200 clinical manuscripts were submitted to thejournal.
Changes are in hand over the membership of the Editorial
Board. Some members have been in place for many years and
the changeover in the journal's publishers has prompted us
to consider appointing new members. The Chairman, David
Harnden, has this well in hand. Members of the Editorial Board
play a major role in the journal, not only considering policy but
also acting as major reviewers of submitted manuscripts. On
behalfof my fellow Editors, I thank all members ofthe Board and
the many hundreds of other scientists and clinicians who also
review manuscripts.
Finally, in welcoming readers and subscribers to the new
arrangement for British Journal ofCancer, may I appeal to all to
keep up the excellent submission rate. I also welcome, from cancer
researchers in all fields, ideas and suggestions for improving
further the standards of British Journal of Cancer. Our editorial
standards will continue to remain very high.
G E Adams
Editor-in-Chief
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